Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on MRNA Expression of the Molecular Markers 1, 3, and 1

Overview

Journal J Oncol

Specialty Oncology

Date 2021 Oct 4

PMID 34603450

Authors

Jingyao Li

Yang Qiu

Junxiu Yi

Xi Liu

Shixin Zhang

Deli Tan

Tao Jing

Yi Liao

Meng Tang

Jie Liu

Haidong Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the clinical significance of the mRNA expression of 1, 3, and 1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens.

Methods: Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of 1, 3, and 1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared.

Results: Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( > 0.05). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909-0.5827, =0.0025). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine (=0.025). In the detected group, the prognosis of patients with low expression of 1 was better than that of patients with high expression of 1 after paclitaxel treatment (=0.0039).

Conclusions: The selection of chemotherapy regimen based on mRNA expression of the 1, 3, and 1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.

References

Liang J, Jin Z, Gao X, Te M, Ge L, Wang C . Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer. Genet Mol Res. 2014; 13(3):5292-8. DOI: 10.4238/2014.July.24.8. View

Gautschi O, Mack P, Davies A, Jablons D, Rosell R, Gandara D . Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2009; 9 Suppl 3:S129-38. DOI: 10.3816/CLC.2008.s.019. View

Santos E, Blaya M, Raez L . Gene expression profiling and non-small-cell lung cancer: where are we now?. Clin Lung Cancer. 2009; 10(3):168-73. DOI: 10.3816/CLC.2009.n.023. View

Hoppe R, Advani R, Ai W, Ambinder R, Aoun P, Armand P . NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. J Natl Compr Canc Netw. 2018; 16(3):245-254. DOI: 10.6004/jnccn.2018.0013. View

Yang Y, Luo X, Xian L . The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014; 9(4):e93997. PMC: 3976369. DOI: 10.1371/journal.pone.0093997. View

Zhang Z, Tian X, Wu R, Liang Y, Jin X . Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev. 2012; 13(6):2583-6. DOI: 10.7314/apjcp.2012.13.6.2583. View

Jazieh A, Bamefleh H, Demirkazik A, Gaafar R, Geara F, Javaid M . Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 2010; 8 Suppl 3:S16-21. DOI: 10.6004/jnccn.2010.0118. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Besse B, Olaussen K, Soria J . ERCC1 and RRM1: ready for prime time?. J Clin Oncol. 2013; 31(8):1050-60. DOI: 10.1200/JCO.2012.43.0900. View

10.

Bepler G, Olaussen K, Vataire A, Soria J, Zheng Z, Dunant A . ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011; 178(1):69-78. PMC: 3069904. DOI: 10.1016/j.ajpath.2010.11.029. View

11.

Brunelli A, Pompili C, Salati M, Refai M, Berardi R, Mazzanti P . Preoperative maximum oxygen consumption is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. Ann Thorac Surg. 2014; 98(1):238-42. DOI: 10.1016/j.athoracsur.2014.04.029. View

12.

Wang M, Li W, Xing X, Zhang D, Lei J, Li G . BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy. Oncotarget. 2017; 8(46):80869-80877. PMC: 5655245. DOI: 10.18632/oncotarget.20715. View

13.

Cortellini A, Tiseo M, Banna G, Cappuzzo F, Aerts J, Barbieri F . Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50. Cancer Immunol Immunother. 2020; 69(11):2209-2221. PMC: 11027629. DOI: 10.1007/s00262-020-02613-9. View

14.

Higgins K, Chino J, Marks L, Ready N, DAmico T, Clough R . Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 75(5):1462-7. DOI: 10.1016/j.ijrobp.2009.01.069. View

15.

Berardi R, Rinaldi S, Santoni M, Newsom-Davis T, Tiberi M, Morgese F . Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget. 2016; 7(18):26916-24. PMC: 5042025. DOI: 10.18632/oncotarget.8309. View

16.

Simon G, Schell M, Begum M, Kim J, Chiappori A, Haura E . Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2011; 118(9):2525-31. PMC: 3270127. DOI: 10.1002/cncr.26522. View

17.

Cufer T, Knez L . Update on systemic therapy of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2014; 14(10):1189-203. DOI: 10.1586/14737140.2014.940327. View

18.

Friboulet L, Olaussen K, Pignon J, Shepherd F, Tsao M, Graziano S . ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 2013; 368(12):1101-10. PMC: 4054818. DOI: 10.1056/NEJMoa1214271. View

19.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos A, Beau-Faller M . High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther. 2012; 11(5):1203-13. DOI: 10.1158/1535-7163.MCT-11-0899. View

20.

Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow C . A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res. 2013; 19(6):1577-86. PMC: 3619002. DOI: 10.1158/1078-0432.CCR-12-2321. View